Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.37 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252251 | 0.81 | IDO1 (0.43) | IDO1CTSSCTSKPPARAPPARG | |
| SCHEMBL8776174 | 0.80 | SSTR4 (0.39) | SSTR4CTSSCTSKCTSLCTSB | |
| SCHEMBL8307743 | 0.79 | CTSK (0.44) | SSTR4CTSSCTSKCTSLCTSB | |
| SCHEMBL7357403 | 0.76 | CTSS (0.51) | SSTR4CTSSCTSKACECTSL | |
| SCHEMBL28908633 | 0.75 | SSTR4 (0.41) | SSTR4CTSSCTSKCTSLCTSB | |
| SCHEMBL5870601 | 0.74 | SSTR4 (0.41) | SSTR4 | |
| SCHEMBL28695449 | 0.73 | ITGB3 (0.48) | CTSSCTSKACE | |
| SCHEMBL31252212 | 0.73 | CTSK (0.38) | SSTR4IDO1CTSSCTSKCTSL | |
| SCHEMBL9852723 | 0.72 | SSTR4 (0.44) | SSTR4 | |
| SCHEMBL28576006 | 0.71 | SSTR4 (0.43) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | SSTR4 2532/4885IDO1 235/4885CTSS 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.